Apellis Pharmaceuticals, Inc. (APLS) financial statements (2020 and earlier)

Company profile

Business Address 100 FIFTH AVENUE
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments352176176
Cash and cash equivalents352176176
Prepaid expense20245
Other current assets100
Other undisclosed current assets 11
Total current assets:373202182
Noncurrent Assets
Operating lease, right-of-use asset14
Property, plant and equipment2  
Other noncurrent assets010
Total noncurrent assets:1610
TOTAL ASSETS:389204182
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities63157
Accounts payable8104
Accrued liabilities5553
Debt32 
Total current liabilities:66177
Noncurrent Liabilities
Long-term debt and lease obligation1541920
Long-term debt, excluding current maturities1431920
Operating lease, liability12
Liabilities, other than long-term debt 77
Due to related parties 77
Other undisclosed noncurrent liabilities13500
Total noncurrent liabilities:2892627
Total liabilities:3554333
Stockholders' equity
Stockholders' equity attributable to parent34161149
Common stock000
Additional paid in capital616438298
Accumulated other comprehensive loss(0)(0) 
Accumulated deficit(581)(277)(149)
Total stockholders' equity:34161149
TOTAL LIABILITIES AND EQUITY:389204182

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Operating expenses(288)(128)(51)
Operating loss:(288)(128)(51)
Nonoperating income530
Investment income, nonoperating53 
Other nonoperating income (expense)(0)(0)0
Interest and debt expense(2)  
Other undisclosed loss from continuing operations before equity method investments, income taxes(20)  
Loss before gain (loss) on sale of properties:(305)(125)(51)
Other undisclosed net loss (2) 
Net loss:(305)(128)(51)
Other undisclosed net loss attributable to parent  (0)
Net loss available to common stockholders, diluted:(305)(128)(51)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Net loss:(305)(128)(51)
Comprehensive loss:(305)(128)(51)
Other undisclosed comprehensive loss, net of tax, attributable to parent(0)(0) 
Comprehensive loss, net of tax, attributable to parent:(305)(128)(51)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: